Therapie der Endometriose

Ludwig Kiesel, Karin Bertges, T. Rabe, Th. von Holst, B. Runnebaum
In: Gynäkologie und Geburtshilfe 1988 · 1989 · pp. 937–940 · doi:10.1007/978-3-642-74784-7_482 · W2412349714
book-chapter OA: closed CC0 ⤵ 5 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Gestrinone and danazol showed similar efficacy and pregnancy rates in endometriosis treatment, but with differing side effects, while buserelin achieved implant reduction in 80% of patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper compares hormonal therapies for endometriosis using randomized data in 30 laparoscopically proven patients treated for 6 months with gestrinone versus danazol, reporting effective treatment in roughly 80–90% of cases and similar pregnancy rates, alongside different side-effect profiles between groups. It also describes a multinational, multicenter trial of buserelin (GnRH agonist) in 275 patients, where in 80% the treatment led to disappearance or reduction of endometriotic implants, with main side effects attributed to estrogen suppression. A key limitation stated in the summary is the ongoing investigation of different hormonal methods, especially regarding recurrence rates and long-term side effects rather than definitive long-term outcomes. This paper is centrally about endometriosis — it evaluates and summarizes randomized trial outcomes for gestrinone, danazol, and buserelin in treating endometriotic implants and compares their efficacy and side effects.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (5)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK